Serum Pirna-54265 is a New Biomarker for Early Detection and Clinical Surveillance of Human Colorectal Cancer
Dongmei Mai,Yanfen Zheng,Huan Guo,Peirong Ding,Ruihong Bai,Mei Li,Ying Ye,Jialiang Zhang,Xudong Huang,Dingxin Liu,Qiaoqi Sui,Ling Pan,Jiachun Su,Junge Deng,Guandi Wu,Rui Li,Shuang Deng,Yansen Bai,Yanan Ligu,Wen Tan,Chen Wu,Tangchun Wu,Jian Zheng,Dongxin Lin
DOI: https://doi.org/10.7150/thno.46241
IF: 11.6
2020-01-01
Theranostics
Abstract:Background: Our previous study has demonstrated an oncogenic role of PIWI-interacting RNA-54265 (piR-54265) in colorectal cancer (CRC). Here, we investigate whether it can be a blood biomarker for population screening and clinical applications. Methods: Serum piR-54265 levels were determined by a digital PCR method in 209 cancer-free healthy controls, 725 patients with CRC, 1303 patients with other types of digestive cancer and 192 patients with benign colorectal tumors. A prospective case-control analysis was conducted to assess the predictive value of serum piR-54265 for future CRC diagnosis. Receiver operating characteristic (ROC) curve was constructed to quantify the diagnostic performance of serum piR-54265 levels by assessing its sensitivity, specificity and respective areas under curve (AUC). The odds ratios (ORs) were computed using multivariate logistic regression models. Results: Serum piR-54265 levels were significantly elevated only in patients with CRC compared with controls and patients with other cancer types. The AUC for recognizing CRC was 0.896 (95% CI, 0.874-0.914), with a sensitivity and specificity being 85.7% and 65.1% at 1500 copies/µL as a cut-off value. The serum piR-54265 levels in patients declined substantially after surgery but increased significantly again when tumor relapses. The prediagnostic serum piR-54265 levels were significantly associated with future CRC diagnosis, with the ORs of 7.23, 2.80, 2.45, and 1.24 for those whose CRC was diagnosed within 1, 2, 3 and >3 years. Serum piR-54265 test is more sensitive than other blood CRC markers. Conclusion: Serum piR-54265 may serve as a valuable biomarker for CRC screening, early detection and clinical surveillance.